|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Provision for doubtful accounts | |||||
| Deferred income taxes | |||||
| Release of uncertain tax positions | |||||
| Goodwill impairment | |||||
| Non-cash compensation expense | |||||
| Non-cash interest expense | |||||
| Fair market value adjustment to investment in private company | |||||
| Dilution gain on equity method investee share issuance | |||||
| Loss allocations from equity method investments | |||||
| Gain on life insurance proceeds | |||||
| Lease related impairments | |||||
| Gain (loss) on extinguishment of debt | |||||
| Convertible Notes due 2023 | |||||
| Convertible Notes due 2025 | |||||
| Accretion on contingent consideration and purchase liability | |||||
| Loss on property and equipment disposals | |||||
| Payments of contingent consideration | |||||
| Fair market value adjustment to contingent consideration liability | |||||
| Gain on settlement of liability | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Fees receivable, net | |||||
| Prepaid expenses and other assets | |||||
| Other non-current assets | |||||
| Accrued expenses and other liabilities | |||||
| Accounts payable | |||||
| Accounts payable, accrued expenses and other liabilities | |||||
| Deferred revenue | |||||
| Other non-current liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Capitalization of internally developed software | |||||
| Acquisitions of businesses, net of cash acquired | |||||
| Investments in private companies | |||||
| Acquisition of proprietary technology | |||||
| Proceeds from life insurance policy | |||||
| Advance for technology solutions | |||||
| Issuance of loan receivable to private company | |||||
| Issuance of note receivable to equity method investees | |||||
| Other | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from borrowings under Revolving Credit Facility | |||||
| Payments related to Revolving Credit Facility | |||||
| Settlement of Convertible Notes due 2023 | |||||
| Proceeds from convertible debt | |||||
| Convertible Notes due 2025 | |||||
| Convertible Notes due 2027 | |||||
| Total proceeds from convertible debt | |||||
| Debt issuance cost | |||||
| Convertible Notes due 2025 | |||||
| Revolving credit facility | |||||
| Convertible Notes due 2027 | |||||
| Payments related to Capped Call Transactions | |||||
| Proceeds from exercise of stock options | |||||
| Payments related to tax withholdings for stock-based compensation | |||||
| Payments related to share repurchases | |||||
| Finance lease payments | |||||
| Purchase of non-controlling units from third-party shareholders | |||||
| Proceeds from capital contributions of non-controlling shareholders | |||||
| Payments of deferred consideration on prior acquisitions | |||||
| Payments of contingent consideration | |||||
| Other | |||||
| Net cash used in financing activities | |||||
| Effect of exchange rate on changes on cash, cash equivalents and restricted cash | |||||
| Net change in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash, beginning of period | |||||
| Cash, cash equivalents and restricted cash, end of period | |||||
| Net cash paid for income taxes | |||||
| Cash paid for interest | |||||
| Supplemental disclosure of non-cash activities | |||||
| Common stock issued in acquisition of business | |||||
| Purchase of fixed assets included in accounts payable and accrued expenses and other current liabilities | |||||
| Property and equipment acquired through financing leases | |||||
| Transfer of non-controlling units | |||||
| Right-of-use assets obtained in exchange for lease liabilities, net | |||||
| Conversion of equity method investee loan to shares | |||||
| Total conversion of equity method investee loan to shares | |||||
| Treasury stock purchases included in accrued expenses and other liabilities | |||||
| Membership interest liabilities included in other liabilities | |||||
| Common stock issued to settle purchase liability | |||||
| Contingent consideration issued in acquisition of businesses | |||||
| Internally developed software costs included in accrued expenses and other liabilities | |||||
| Leasehold improvements funded by lease incentive | |||||
| Purchase liabilities included in accrued expenses and other liabilities | |||||
| Purchase liabilities included in other non-current liabilities | |||||
Loading...